Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levamlodipine maleate - CSPC Ouyi Pharmaceutical

Next Previous
Drug Profile

Levamlodipine maleate - CSPC Ouyi Pharmaceutical

Alternative Names: Levamlodipine maleate dispersible tablet - CSPC Ouyi Pharmaceutical; Levamlodipine maleate tablet - CSPC Ouyi Pharmaceutical; Xuanning

Latest Information Update: 28 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Ouyi Pharmaceutical
  • Developer Conjupro Biotherapeutics; CSPC Ouyi Pharmaceutical
  • Class Antihypertensives; Dihydropyridines; Nicotinic acids; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris; Hypertension

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in USA (PO, Tablet)
  • 06 Sep 2018 CSPC Ouyi Pharmaceutical and Conjupro Biotherapeutics completes phase I trial in Hypertension (In volunteers) in USA (NCT03657550)
  • 31 May 2018 Phase-I clinical trials in Hypertension (In volunteers) in USA (PO) (NCT03657550)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top